If it feels like the entire pharma world now runs on clinical trials, that’s because it more or less does. We’ve gone from a few thousand registered studies to hundreds of thousands, and well over half a million on major registries. The industry pours hundreds of millions into the clinical phase of a single drug candidate, and somehow the pipeline keeps getting fuller, not emptier. The question is no longer “can we run more trials?” but “what, exactly, are we willing to ask people to do in them?”
On paper, clinical trial ethics are straightforward. Treat participants as people, not datapoints. Make sure they understand what they’re signing up for. Design studies with a real chance to produce useful knowledge, balance risk against potential benefit, and avoid unnecessary harm. Layer on fairness in who’s included, independent ethics review, and a promise that the pursuit of progress never outruns respect for the volunteer in the chair—or on the OR table.
Which brings us to the FDA’s “strong recommendation” for uniQure’s Huntington’s disease program. To get the data it wants, the agency is asking for a Phase 3 trial in which some participants undergo sham brain surgery: holes drilled, instruments inserted, but no gene therapy delivered. We’re not talking about a sugar pill here.
Proponents will say desperate patients will consent, that the science demands a clean comparison, that this is the price of certainty. But consent under the shadow of a fatal, progressive disease is a complicated kind of “yes,” and ethics has always been about drawing lines precisely where the science gets most tempting. When “do no harm” starts to sound like “do brain surgery on people who will not receive the therapy,” it may be time to ask whether our devotion to methodological purity has drifted a bit too far from the values we claim to live by—and who, exactly, is paying the price for our comfort with that.
Mike Auerbach
Pharma Group Editor-in-Chief
mauerbach@comparenetworks.com
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!